![[PDF]](/pb-assets/Icons/adobe-pdf-icon-1498649896243.png){kind=icon}
Abstract
Pharmacokinetics may be defined as what the body does to a drug. It deals with the absorption, distribution, and elimination of drugs but also has utility in evaluating the time course of environmental (exogenous) toxicologic agents as well as endogenous compounds. An understanding of 4 fundamental pharmacokinetic parameters will give the toxicologic pathologist a strong basis from which to appreciate how pharmacokinetics may be useful. These parameters are clearance, volume of distribution, half-life, and bioavailability.
|
Benet LZ (1984). Pharmacokinetic parameters: Which are necessary to define a drug substance? Eur. J. Resp. Dis. 65(suppl.134): 45-61. Google Scholar | |
|
Benet LZ (1994). Pharmacokinetics profile of etodolac in special populations. Eur. J. Rheumatol. Inflam. 14: 15-18. Google Scholar | Medline | |
|
Benet LZ and Galeazzi RL (1979). Noncompartmental determination of the steady-state volume of distribution. J. Pharm. Sci. 68: 1971-1974. Google Scholar | Crossref | |
|
Benet LZ. Massoud N. and Gambertoglio JG (eds) ( 1984). The Pharmacokinetic Basis for Drug Treatment . Raven Press. New York. Google Scholar | |
|
Benet LZ Mitchell JR , and Sheiner LB (1990). Pharmacokinetics : The dynamics of drug absorption, distribution. and elimination. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, AG Gilman , TW Rall , AS Nies , and P Taylor (eds). Pergamon Press. New York . pp. 3-32. Google Scholar | |
|
Benet LZ and Williams RL (1990). Design and optimization ofdosage regimens: pharmacokinetic data. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, AG Gilman , TW Rall , AS Nies , and P Taylor (eds). Pergamon Press, New York, pp. 1650-1735. Google Scholar | |
|
Brater DC (1985). Renal safety profile of etodolac. In: Etodolac: Clinical Perspectives in Antiarthritic Therapy, TG Kantor (ed). Royal Society of Medicine Services Limited, London, pp. 37-43. Google Scholar | |
|
Gibaldi M. and Perrier D. (1982). Pharmacokinetics, 2nd ed. Marcel Dekker, New York. Google Scholar | |
|
Hebert MF , Roberts JP , Prueksaritanont T. , and Benet LZ (1992). Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52: 453-457. Google Scholar | Crossref | Medline | |
|
Klotz U. , Avant GR , Hoyumpa A. , Schenker S. , and Wilkinson GR (1975). The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J. Clin. Invest . 55: 347-359. Google Scholar | Crossref | Medline | |
|
Rowland M. , Benet LZ , and Graham GG (1973). Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1: 123-135. Google Scholar | Crossref | Medline | |
|
Rowland M. and Tozer TN (1989). Clinical Pharmacokinetics, 2nd ed. Lea & Febiger, Philadelphia . Google Scholar | |
|
Wilkinson G. and Shand DG (1975). The physiological approach to hepatic blood clearance. Clin. Pharmacol. Ther . 18: 377-390. Google Scholar | Crossref | Medline | |
|
Williams RL , Blaschke TF , Meffin PJ , Melmon KL , and Rowland M. (1977). Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide . Clin. Pharmacol. Ther. 21: 301-309. Google Scholar | Crossref | Medline | |
|
Winter ME (1988). Baste Chmcal Pharmacokinetics, 2nd ed. Applied Therapeutics, Spokane , Washington. Google Scholar |
